CT-Guided 125I Brachytherapy in the Treatment of Hepatocellular Carcinoma Refractory to Conventional Transarterial Chemoembolization : A Pilot Study
© 2021 Xu et al..
PURPOSE: To investigate the efficacy and safety of CT-guided 125I brachytherapy in the treatment of hepatocellular carcinoma (HCC) refractory to conventional transarterial chemoembolization (TACE).
METHODS: Nineteen patients with TACE-refractory HCC treated with CT-guided 125I brachytherapy between June 2017 and June 2020 at Jiangyin People's Hospital were enrolled in this study. In addition, we used the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria to evaluate the treatment response after 125I brachytherapy.
RESULTS: Twenty-one tumours were treated with CT-guided 125I brachytherapy in nineteen patients. Twelve tumours (57.1%) showed a complete response, and a partial response was observed in seven tumours (33.3%). The six-month objective response rate was 90.5% (19/21). The adverse effects of CT-guided 125I brachytherapy were tolerable.
CONCLUSION: Our preliminary clinical experience demonstrated that CT-guided 125I brachytherapy was effective and well tolerated for the treatment of TACE-refractory HCC, suggesting that CT-guided 125I brachytherapy has the potential to become an effective alternative treatment for TACE-refractory HCC.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
---|---|
Enthalten in: |
Cancer management and research - 13(2021) vom: 30., Seite 3317-3326 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Xu, Xinjian [VerfasserIn] |
---|
Links: |
---|
Themen: |
125I brachytherapy |
---|
Anmerkungen: |
Date Revised 11.11.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.2147/CMAR.S305422 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM324382618 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM324382618 | ||
003 | DE-627 | ||
005 | 20231225190215.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2147/CMAR.S305422 |2 doi | |
028 | 5 | 2 | |a pubmed24n1081.xml |
035 | |a (DE-627)NLM324382618 | ||
035 | |a (NLM)33883943 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Xu, Xinjian |e verfasserin |4 aut | |
245 | 1 | 0 | |a CT-Guided 125I Brachytherapy in the Treatment of Hepatocellular Carcinoma Refractory to Conventional Transarterial Chemoembolization |b A Pilot Study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 11.11.2023 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a © 2021 Xu et al. | ||
520 | |a PURPOSE: To investigate the efficacy and safety of CT-guided 125I brachytherapy in the treatment of hepatocellular carcinoma (HCC) refractory to conventional transarterial chemoembolization (TACE) | ||
520 | |a METHODS: Nineteen patients with TACE-refractory HCC treated with CT-guided 125I brachytherapy between June 2017 and June 2020 at Jiangyin People's Hospital were enrolled in this study. In addition, we used the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria to evaluate the treatment response after 125I brachytherapy | ||
520 | |a RESULTS: Twenty-one tumours were treated with CT-guided 125I brachytherapy in nineteen patients. Twelve tumours (57.1%) showed a complete response, and a partial response was observed in seven tumours (33.3%). The six-month objective response rate was 90.5% (19/21). The adverse effects of CT-guided 125I brachytherapy were tolerable | ||
520 | |a CONCLUSION: Our preliminary clinical experience demonstrated that CT-guided 125I brachytherapy was effective and well tolerated for the treatment of TACE-refractory HCC, suggesting that CT-guided 125I brachytherapy has the potential to become an effective alternative treatment for TACE-refractory HCC | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a 125I brachytherapy | |
650 | 4 | |a TACE | |
650 | 4 | |a hepatocellular carcinoma | |
650 | 4 | |a refractory | |
700 | 1 | |a Ding, Yiwen |e verfasserin |4 aut | |
700 | 1 | |a Pan, Tianfan |e verfasserin |4 aut | |
700 | 1 | |a Gao, Feng |e verfasserin |4 aut | |
700 | 1 | |a Huang, Xiangzhong |e verfasserin |4 aut | |
700 | 1 | |a Sun, Qiulian |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer management and research |d 2009 |g 13(2021) vom: 30., Seite 3317-3326 |w (DE-627)NLM197692605 |x 1179-1322 |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2021 |g day:30 |g pages:3317-3326 |
856 | 4 | 0 | |u http://dx.doi.org/10.2147/CMAR.S305422 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 13 |j 2021 |b 30 |h 3317-3326 |